Neuronostics

Neuronostics, founded in 2018 and headquartered in the United Kingdom, is revolutionizing the diagnosis and prognosis of neurological conditions. The company's slogan, "Revolutionising diagnosis and prognosis of neurological conditions," encapsulates their mission. Neuronostics utilizes mathematical modeling to develop novel biomarkers, creating faster paths to diagnosis and effective treatment. With BioEP as their first clinical indication, they have introduced a digital biomarker for epilepsy, which utilizes background EEG data and mathematical modeling to predict the likelihood of seizures. This innovation supports clinical diagnostic and prognostic decisions for epilepsy. The recent £2.10M Seed Round investment on 05 April 2024, with contributions from QantX, Cornwall & Isles of Scilly Investment Fund, Empirical Ventures, and Ascension Life Fund, signifies confidence in Neuronostics' potential to transform neurological healthcare and improve the lives of individuals at risk of or living with neurological conditions. The company's vision of integrating digital biomarkers into neurology centers worldwide is poised to create a proactive and anticipatory model of care, ultimately revolutionizing neurological healthcare.